medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2013, Number 3

<< Back Next >>

Residente 2013; 8 (3)

Las adipocinas como mediadoras en la inflamación y el sistema inmune

Nava-Santana CA, Guerra-Soto AJ, Mendoza-Vázquez G, Flores-Chávez A, Nava A

Language: Spanish
References: 53
Page: 97-105
PDF size: 400.06 Kb.


ABSTRACT

Obesity represents a pandemic that increases mortality mainly from cardiovascular sources, with inflammatory process playing a main role in the physiopatogenesis. Adipokines are first line mediators for this process; they include several proinflammatory peptides conditioning a subclinical inflammatory status associated with metabolic disorders that contribute to the cardiovascular outcomes. This paper describes how the adipose tissue is now considered as a secretory organ of these adipokines, and the most recent findings regarding the role of adipokines in the immune and inflammatory response.


REFERENCES

  1. Zimmermann-Belsing T, Feldt-Rasmussen U. Obesity: the new worldwide epidemic threat to general health and our complete lack of effective treatment. Endocrinology. 2004; 145 (4): 1501-1502.

  2. Prins JB. Adipose tissue as an endocrine organ. Best Pract Res Clin Endocrinol Metab. 2002; 16 (4): 639-651.

  3. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 2003; 14 (3): 137-45.

  4. Spiegelman BM, Enerback S. The adipocyte: a multifunctional cell. Cell Metab. 2006; 4 (6): 425-427.

  5. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006; 55: 1537-1545.

  6. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab. 2001; 280 (6): E827-E847.

  7. Moreno-Aliaga MJ, Campión J, Milagro FI, Berjón A, Martínez JA. Adiposity and proinflammatory state: the chicken or the egg. Adipocytes. 2005; 1: 1-16.

  8. Sjoholm A, Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev. 2006; 22 (1): 4-10.

  9. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259: 87-91.

  10. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6: 772-783.

  11. Gómez R, Conde J, Gómez-Reino JJ, Lago F, Gualillo O. Adipocytokines: emerging mediators of the immune response and inflammation. Reumatol Clin. 2009; (Suppl. 1): 6-12.

  12. Sánchez JC, López D, Pinzón A, Sepúlveda JC. Adipokines and metabolic syndrome: multiple aspects of a complex pathophysiological process. Revista Colombiana de Cardiología. 2010; 17 (4): 167-176.

  13. Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest. 2011; 121 (6): 2087.

  14. Parul Singla, Animesh Bardoloi, Anuj A Parkash. Metabolic effects of obesity: a review. World J Diabetes. 2010; 1 (3): 76-88.

  15. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372 (6505): 425.

  16. Nawrot-Porabka K, Jaworek J, Leja-Szpak A, Palonek M, Szklarczyk J, Konturek SJ et al. Leptin is able to stimulate pancreatic enzyme secretion via activation of duodeno-pancreatic reflex and CCK release. J Physiol Pharmacol. 2004; 55 (Suppl. 2): 47-57.

  17. Botella C, Barbancho LL, González V, Varela D. Leptina: implicaciones fisiológicas y clínicas. An Med Interna. 2001; 18 (3): 152-160.

  18. Toussirot E, Gaugler B, Bouhaddi M, Nguyen N, Saas P, Dumoulin G. Elevated adiponectin serum levels in women with systemic autoimmune diseases. 2010; 2010: [6 p.]. pii: 938408. doi:10.1155/2010/938408.

  19. Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. Diabetología. 1973; 9 (4): 294.

  20. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334 (5): 292.

  21. Sinha MK et al. Nocturnal rise of leptin in lean, obese and non-insulin dependent diabetes mellitus subjects. J Clin Invest. 1996; 97: 1344-1347.

  22. San Miguel A, Calvo B, Alonso N, Iglesias R, Mazón M. Leptina: implicaciones fisiológicas y clínicas. Asociación Española de Farmacéuticos Analistas. 2005; 3: 28010.

  23. Tesauro M, Mascali A, Franzese O, Cipriani S, Cardillo C, Di Daniele N. Chronic kidney disease, obesity, and hypertension: the role of leptin and adiponectin. Int J Hyperten. 2012; 2012: [7 p.]. pii: 943605. doi:10.1155/2012/943605.

  24. Morton GJ. Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol. 2007; 583 (Pt 2): 437-443.

  25. Procaccini C, Lourenco EV, Matarese G, La Cava A. Leptin signaling: a key pathway in immune responses. Curr Signal Transduct Ther. 2009; 4 (1): 22-30.

  26. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002; 110 (8): 1093.

  27. McMahon M, Skaggs BJ, Sahakian L, Grossman J, Fitzgerald J, Ragavendra N et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidisedlipids. Ann Rheum Dis. 2011; 70: 1619-1624.

  28. Scotece M, Conde J, Gómez R, López V, Lago F, Gómez-Reino M. Beyond fat mass: exploring the role of adipokines in rheumatic diseases. Scientific World Journal. 2011; 11: 1932-1947.

  29. Maeda N, Takahashi M, Funahashi T et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50 (9): pp. 2094-2099.

  30. Robinson K, Prins J, Venkatesh B. Clinical review: adiponectin biology and its role in inflammation and critical illness. Crit Care. 2011; 15: 221.

  31. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423: 762-769.

  32. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007; 13: 332-339.

  33. Domínguez C. Adiponectina: el tejido adiposo más allá de la reserva inerte de energía. Revista de Endocrinología y Nutrición. 2007; 15 (3): 149-155.

  34. Gómez R, Conde J, Gómez JJ. Las adipocinas: mediadores emergentes de la respuesta inmune y de la inflamación. J Reuma. 2008; 5: 6-12.

  35. Rovin BH, Song H, Hebert LA et al. Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney International. 2005; 68 (4): 1825-1833.

  36. Sánchez-Muñoz F, García-Macedo R, Alarcón-Aguilar F, Cruz M. Adipocinas, tejido adiposo y su relación con células del sistema inmune. Gac Méd Méx. 2005; 141 (6): 505-512.

  37. Nogueiras R, González RC, Mendieta H, Lage R, Diéguez C. Resistina: una nueva hormona expresada en el tejido adiposo. Revista Esp Obes. 2005; 3 (4): 194-211.

  38. Santana PS. Las adipocitoquinas en la génesis y evolución del síndrome metabólico. Rev Cubana Aliment Nutr. 2010; 20 (2): 304-317.

  39. Zulet MA, Puchau B, Navarro C, Martí A, Martínez JA. Biomarcadores del estado inflamatorio: nexo de unión con la obesidad y complicaciones asociadas. Nutr Hosp. 2007; 22 (5): 511-527. ISSN 0212-1611.

  40. Mohapatra J, Sharma M, Acharya A, Pandya G, Chatterjee A, Balaraman R et al. Retinol-binding protein 4: a possible role in cardiovascular complications. Br J Pharmacol. 2011; 164 (8): 1939-1948.

  41. Kotnik P, Fischer-Posovszky P, Wabitsch M. RBP-4: a controversial adipokine. Eur J Endocrinol. 2011; 165 (5): 703-711.

  42. Keicho N, Matsushita I, Tanaka T, Shimbo T, Hang NT, Sakurada S et al. Circulating levels of adiponectin, leptin, fetuin-a and retinol-binding protein in patients with tuberculosis: markers of metabolism and inflammation. PLoS One. 2012; 7 (6): e38703.

  43. Koch A, Weiskirchen R, Sanson E, Zimmermann HW, Voigt S, Dückers H et al. Circulating retinol-binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Crit Care. 2010; 14 (5): R179.

  44. Bergmann K, Sypniewska G. Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers? Clin Chem Lab Med. 2013; 51 (1): 177-185.

  45. Barazzoni R, Zanetti M, Semolic A, Pirulli A, Cattin MR, Biolo G et al. High plasma RBP-4 is associated with systemic inflammation independently of low RBP-4 adipose expression and is normalized by transplantation in non-obese, non-diabetic patients with chronic kidney disease. Clin Endocrinol. 2011; 75: 56–63. doi: 10.1111/j.1365-2265.2011.03990.x

  46. Farjo KM, Farjo RA, Halsey S, Moiseyev G, Ma JX. Retinol-binding protein 4 induces inflammation in human endothelial cells by an NADPH oxidase-and nuclear factor kappa B-dependent and retinol-independent mechanism. Mol Cell Biol. 2012; 32 (24): 5103-5115.

  47. Iglesias P, Selgas R, Romero S, Díez JJ. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol. 2012; 167 (3): 301-309.

  48. Kotulák T, Drápalová J, Kopecký P, Lacinová Z, Kramář P, Říha H et al. Increased circulating and epicardial adipose tissue mRNA expression of fibroblast growth factor-21 after cardiac surgery: possible role in postoperative inflammatory response and insulin resistance. Physiol Res. 2011; 60 (5): 757-767.

  49. Xu A, Vanhoutte PM. Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol. 2012; 15; 302 (6): H1231-H1240.

  50. Hui X, Li H, Zhou Z, Lam KS, Xiao Y, Wu D et al. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem. 2010; 285 (14): 10273-10280.

  51. Dunmore SJ, Brown JE. The role of adipokines in β-cell failure of type 2 diabetes. J Endocrinol. 2013; 216 (1): T37-T45.

  52. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009; 54 (9): 1847-1856.

  53. Xu S, Tsao PS, Yue P. Apelin and insulin resistance: another arrow for the quiver? J Diabetes. 2011; 3 (3): 225-231.




2020     |     www.medigraphic.com